Shares of Establishment Labs Holdings Inc (NASDAQ:ESTA) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.
Analysts have set a one year consensus target price of $35.00 for the company and are anticipating that the company will post ($0.48) EPS for the current quarter, according to Zacks. Zacks has also assigned Establishment Labs an industry rank of 69 out of 255 based on the ratings given to related companies.
A number of research analysts have commented on the company. Zacks Investment Research lowered Establishment Labs from a “hold” rating to a “sell” rating in a research report on Monday, October 15th. BTIG Research initiated coverage on Establishment Labs in a report on Monday, August 13th. They set a “buy” rating and a $35.00 target price on the stock. Cowen initiated coverage on Establishment Labs in a report on Monday, August 13th. They set an “outperform” rating and a $35.00 target price on the stock. Finally, Jefferies Financial Group initiated coverage on Establishment Labs in a report on Monday, August 13th. They set a “buy” rating and a $35.00 target price on the stock.
Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Tuesday, August 14th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.15. The business had revenue of $13.71 million for the quarter, compared to the consensus estimate of $12.10 million. Analysts expect that Establishment Labs will post -1.66 EPS for the current fiscal year.
About Establishment Labs
Establishment Labs Holdings Inc, a medical technology company, designs, develops, manufactures, and markets medical devices for aesthetic plastic surgery, reconstructive plastic surgery, and aesthetic dermatology. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name.
Featured Story: How accurate is the Rule of 72?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.